Template:Target ranges for hormone levels in hormone therapy for transgender women
Appearance
Source | Place | Estradiol, total | Testosterone, total | Refs |
---|---|---|---|---|
Endocrine Society | United States | 100–200 pg/mL | <50 ng/dL | [1] |
World Professional Association for Transgender Health (WPATH) | United States | "[T]estosterone levels [...] below the upper limit of the normal female range and estradiol levels within a premenopausal female range but well below supraphysiologic levels." "[M]aintain levels within physiologic ranges for a patient's desired gender expression (based on goals of full feminization/masculinization)." | [2] | |
Center of Excellence for Transgender Health (UCSF ) | United States | "The interpretation of hormone levels for transgender individuals is not yet evidence based; physiologic hormone levels in non-transgender people are used as reference ranges." "Providers are encouraged to consult with their local lab(s) to obtain hormone level reference ranges for both 'male' and 'female' norms, [which can vary,] and then apply the correct range when interpreting results based on the current hormonal sex, rather than the sex of registration." | [3] | |
Fenway Health | United States | 100–200 pg/mL | <55 ng/dL | [4] |
Callen-Lorde | United States | "Some guidelines recommend checking estradiol and testosterone levels at baseline and throughout the monitoring of estrogen therapy. We have not found a clinical use for routine hormone levels that justifies the expense. However, we recognize that individual providers may adjust their prescribing and monitoring practices as needed to comply with guidelines or when guided by patient need." | [5] | |
International Planned Parenthood Federation (IPPF) | United Kingdom | <200 pg/mL | 30–100 ng/dL | [6] |
National Health Service (NHS) Foundation Trusts | United Kingdom | 55–160 pg/mL | 30–85 ng/dL | [7][8][9][10] |
Royal College of Psychiatry (RCP) | United Kingdom | 80–140 pg/mL | "Well below normal male range" | [11] |
Vancouver Coastal Health (VCH) | Canada | ND | <1.5 nmol/L | [12] |
Sources: See above. |
Template documentation
References
- ^ Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, Rosenthal SM, Safer JD, Tangpricha V, T'Sjoen GG (November 2017). "Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline" (PDF). J. Clin. Endocrinol. Metab. 102 (11): 3869–3903. doi:10.1210/jc.2017-01658. PMID 28945902.
- ^ Coleman, E.; Bockting, W.; Botzer, M.; Cohen-Kettenis, P.; DeCuypere, G.; Feldman, J.; Fraser, L.; Green, J.; Knudson, G.; Meyer, W. J.; Monstrey, S.; Adler, R. K.; Brown, G. R.; Devor, A. H.; Ehrbar, R.; Ettner, R.; Eyler, E.; Garofalo, R.; Karasic, D. H.; Lev, A. I.; Mayer, G.; Meyer-Bahlburg, H.; Hall, B. P.; Pfaefflin, F.; Rachlin, K.; Robinson, B.; Schechter, L. S.; Tangpricha, V.; van Trotsenburg, M.; Vitale, A.; Winter, S.; Whittle, S.; Wylie, K. R.; Zucker, K. (2012). "Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7" (PDF). International Journal of Transgenderism. 13 (4): 165–232. doi:10.1080/15532739.2011.700873. ISSN 1553-2739.
- ^ Deutsch M (17 June 2016). "Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People" (PDF) (2nd ed.). University of California, San Francisco: Center of Excellence for Transgender Health. p. 28.
- ^ Cavanaugh, Timothy. Cross-Sex Hormone Therapy (PDF) (Report). Fenway Institute. Retrieved 9 May 2019.
- ^ https://web.archive.org/web/20190905231203/http://callen-lorde.org/graphics/2018/05/Callen-Lorde-TGNC-Hormone-Therapy-Protocols-2018.pdf
- ^ IMAP Statement on hormone therapy for transgender people (PDF) (Report). International Planned Parenthood Federation. October 2015.
- ^ https://www.gires.org.uk/wp-content/uploads/2014/08/PG12-GenderDysphoria.pdf
- ^ Barnsley, Rotherham; Sheffield Clinical Commissioning Groups (12 October 2017). Prescribing Guidelines: Trans woman medication (PDF) (Report). NHS.
- ^ Leighton Seal; James Barret (December 2015). GUIDELINES FOR THE USE OF FEMINISING HORMONE THERAPY IN GENDER DYSPHORIA (PDF) (Report). NHS.
- ^ Sunderland Clinical Commissioning Group (14 March 2017). SHARED CARE PRESCRIBING GUIDANCE FOR Treatment of Gender Dysphoria in Transwomen (Male to Female Transsexuals) (PDF) (Report). NHS.
- ^ Wylie, Kevan; Barrett, James; Besser, Mike; Bouman, Walter Pierre; Bridgman, Michelle; Clayton, Angela; Green, Richard; Hamilton, Mark; Hines, Melissa; Ivbijaro, Gabriel; Khoosal, Deenesh; Lawrence, Alex; Lenihan, Penny; Loewenthal, Del; Ralph, David; Reed, Terry; Stevens, John; Terry, Tim; Thom, Ben; Thornton, Jane; Walsh, Dominic; Ward, David; Coleman, Eli; Di Ceglie, Domenico; Martin, Emma; McGarry, Philip; Messenger, Andrew; Reid, Russell; Sethi, Su; Sutcliffe, Paul; Wilson, Daniel; Carr, Susan; Davies, Dai; Dean, Tracey; Ellis, Michelle; Ferguson, Brian; Skinner, Darren; Williams, Vicky; Brechin, Susan; Lucey, Jim; Rathbone, Maxine (2014). "Good Practice Guidelines for the Assessment and Treatment of Adults with Gender Dysphoria" (PDF). Sexual and Relationship Therapy. 29 (2): 154–214. doi:10.1080/14681994.2014.883353. ISSN 1468-1994.
- ^ Dahl, M; Feldman, JL; Goldberg, J; Jaberi, A (2015). "Endocrine Therapy for Transgender Adults in British Columbia: Suggested Guidelines" (PDF). Vancouver Coastal Health. Retrieved 15 August 2018.